Inmune Bio, Inc. 8-K

What Happened

• Inmune Bio, Inc. (INMB) filed an 8-K on February 23, 2026 announcing a live webinar to discuss the registrational pathway for XPro1595 (XPro™), its investigational therapy for early Alzheimer’s disease.
• The webinar is scheduled for February 27, 2026 at 9:30 a.m. ET. A press release dated February 23, 2026 describing the event is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 23, 2026 (Form 8-K, Item 8.01 — Other Events).
• Webinar date/time: February 27, 2026 at 9:30 a.m. Eastern Time.
• Topic: Registrational pathway for XPro1595 (XPro™) in early Alzheimer’s disease.
• Press release attached as Exhibit 99.1 and incorporated by reference.

Why It Matters

• This disclosure communicates that Inmune Bio is publicly presenting its plan for a regulatory/clinical path toward registration of XPro1595, a key development-program update for investors focused on the company’s pipeline.
• While the 8-K does not include new clinical data or financial information, the webinar may provide details on study design, regulatory strategy, or timelines that could be relevant to assessing the program’s progress and potential future milestones.